10% liquid human immunoglobulin (KIOVIG®) for immunomodulation in autoimmune disorders

Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases

(2016) Patrick Cherin et al.   AUTOIMMUNITY REVIEWS

Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines

(2016) Yusuke Mimura et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study

(2016) Van-Mai Cao-Lormeau et al.   LANCET

Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study

(2015) Bohumír Blažek et al.   Immunotherapy

(1) Safety of Intravenous Immunoglobulin Therapy in Patients with Probable Alzheimer's Disease: A Randomized, Placebo-Controlled Clinical Study

(2015) David Gelmont et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity

(2015) Isaak Quast et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth

(2015) Nevena Tzekova et al.   Journal of Neuroinflammation

Intravenous immunoglobulin in neurology—mode of action and clinical efficacy

(2015) Jan D. Lünemann et al.   Nature Reviews Neurology

Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database

(2015) Roger Berg et al.   TRANSFUSION

Thromboembolic events associated with immune globulin preparations: spontaneous pharmacovigilance data versus claims-based data

(2015) Roger Berg et al.   TRANSFUSION

Intravenous immunoglobulin-related thromboembolic events - an accusation that proves the opposite

(2014) M. Basta   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab′)2versus Fc sialylation

(2014) I. Schwab et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis

(2014) Bianca van den Berg et al.   Nature Reviews Neurology

Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075)

(2014) Clive H. Dash et al.   PLoS One

Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012

(2014) Gayathri Sridhar et al.   TRANSFUSION

Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy

(2013) Muhajir Mohamed et al.   BRITISH JOURNAL OF HAEMATOLOGY

Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells

(2013) A. S. W. Tjon et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute

(2013) Miglena G. Prabagar et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders

(2013) L. H. Markvardsen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy

(2013) K. Kuitwaard et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Epidemiology of Kawasaki Disease: Prevalence from National Database and Future Trends Projection by System Dynamics Modeling

(2013) San-Kuei Huang et al.   JOURNAL OF PEDIATRICS

A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy

(2013) Angelika F. Hahn et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G

(2013) Shohei Ogata et al.   PLoS One

Thromboembolic events associated with immunoglobulin treatment

(2013) M. B. Funk et al.   VOX SANGUINIS

Should Therapeutic Immunoglobulin Be Considered a Generic Product? An Evidence-based Approach

(2013) Siraj A. Misbah   Journal of Allergy and Clinical Immunology-In Practice

The Advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade

(2012) Nina Svetlicky et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases

(2012) Erwin W. Gelfand   NEW ENGLAND JOURNAL OF MEDICINE

Kawasaki Disease: An Update on Diagnosis and Treatment

(2012) Ho-Chang Kuo et al.   Pediatrics and Neonatology

Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice

(2012) Ajay Jain et al.   ARTHRITIS RESEARCH & THERAPY

The experience of Flebogammadif® in primary immune thrombocytopenia

(2011) A. Julia   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Autoimmunity and Environment: Am I at risk?

(2011) Daniel Smyk et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Advances in the diagnosis, pathogenesis and treatment of CIDP

(2011) Marinos C. Dalakas   Nature Reviews Neurology

Genomics and the Multifactorial Nature of Human Autoimmune Disease

(2011) Judy H. Cho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura

(2011) J. W. M. van der Meer et al.   VOX SANGUINIS

Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam®10%) in patients with immune thrombocytopenia

(2010) Tadeusz Robak et al.   Hematology

The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders

(2010) Mark Ballow   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy

(2010) K. Kuitwaard et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome

(2009) Krista Kuitwaard et al.   ANNALS OF NEUROLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Incidence and prevalence of CIDP and the association of diabetes mellitus

(2009) R. S. Laughlin et al.   NEUROLOGY

Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders

(2009) P. Imbach et al.   VOX SANGUINIS

Unlabeled uses of intravenous immune globulin

(2008) H. Leong et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb

(2008) Sofia E. Magnusson et al.   CLINICAL IMMUNOLOGY

A newer immunoglobulin intravenous (IGIV) – Gammagard®liquid 10%: Evaluation of efficacy, safety, tolerability and impact on patient care

(2008) Sachin R Shah   EXPERT OPINION ON BIOLOGICAL THERAPY

History of Immunoglobulin Replacement

(2008) Martha M. Eibl   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy

(2008) E. A. Cats et al.   JOURNAL OF NEUROLOGY

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

(2008) Pieter A van Doorn et al.   LANCET NEUROLOGY

The Epidemiology of Guillain-Barré Syndrome Worldwide

(2008) Anita McGrogan et al.   NEUROEPIDEMIOLOGY

Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis

(2008) Zohra Daw et al.   TRANSFUSION

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity

(2008) G. Poelsler et al.   VOX SANGUINIS

Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion

(2007) J. Chang et al.   BLOOD